Analyst Predicts Housing 'Reset' Ahead: Consider These 5 Stocks for Investment.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Source: Barron's
Housing Market Impact: Housing cost concerns are heightened due to the ongoing war in Iran, affecting the spring buying season.
Investment Opportunity: An analyst suggests that the current market conditions present an attractive entry point for residential real estate stocks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REAX
Wall Street analysts forecast REAX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.620
Low
6.00
Averages
7.00
High
8.00
Current: 1.620
Low
6.00
Averages
7.00
High
8.00
About REAX
The Real Brokerage Inc. is a real estate technology company that operates as a software-based brokerage across approximately 50 states in United Stated, the District of Columbia, and four Canadian provinces. Its platform leverages artificial intelligence (AI) and automation to enhance agent productivity while maintaining a lean operating model. The Company operates as a fully digital brokerage, offering agents a more flexible, efficient, and financially compelling model. Its technology platform is reZEN, is a proprietary transaction management and brokerage operations software. The Company’s services include end-to-end transaction management, automated compliance & brokerage oversight, integrated payment & financial services, Leo CoPilot: AI-powered agent support, and open application programming interface (API) for customization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NŌVEM Real Estate Joins Real Brokerage, Expanding NYC Presence
- Team Expansion: The 10-agent NŌVEM Real Estate team, focusing on luxury markets, joins Real Brokerage, enhancing its presence across key New York areas including Manhattan, Brooklyn, Queens, Long Island, and Westchester County.
- Agent Support Model: Founder Ethan Leifer aims to provide high-level service and support to agents, creating a highly supportive environment that allows agents to access essential resources at all career stages, thereby enhancing their personal brands.
- Industry Experience: Leifer brings over $1 billion in real estate transactions from his 13-year career, which will help Real strengthen its position in a competitive market.
- Technology and Cultural Edge: Leifer expressed admiration for Real's technology and culture, stating these elements set the company apart and effectively support agent growth and business expansion.
See More
Real Brokerage Expands into New Brunswick, Strengthening Canadian Presence
- Market Expansion: Real Brokerage Inc. expands into New Brunswick by acquiring Creativ Realty, adding 42 agents and further solidifying its market presence in Canada, marking the company's sixth province in the country.
- Sales Performance: Creativ Realty generated over $300 million in sales volume in 2025, serving all price points including the luxury market, demonstrating its strong market influence and customer base.
- Leadership Transition: Martin Gallant joins as Managing Broker for the province, bringing years of leadership experience aimed at driving Real's growth in New Brunswick and supporting future expansion opportunities across Canada.
- Cultural Alignment: Gallant noted that Real's culture aligns closely with Creativ Realty's collaborative environment, and the advantages of the technology platform and fee structure make this partnership compelling, with strong interest expected from agents looking to join.
See More
Real Brokerage Expands Kansas City Market Presence
- Agent Growth: Real Brokerage Inc. expands its agent base by 50% through the acquisition of Chartwell Realty LLC, increasing its total to over 450 agents, significantly enhancing its market share in Kansas City and solidifying its position as a leading destination for high-performing agents and teams.
- Transaction Volume: Chartwell Realty closed approximately 1,200 transactions in 2025, totaling $500 million in sales volume, ranking as the top independent full-service brokerage in Kansas City, showcasing its strong market competitiveness and operational capabilities.
- Cultural Fit and Tech Integration: The addition of Chartwell is driven by cultural alignment and the opportunity to leverage Real's technology platform for agent growth, indicating Real's ongoing momentum in attracting top-performing agents and teams, thereby enhancing its market appeal.
- Training and Support Advantage: Chartwell is renowned for its strong emphasis on training, technology, and agent support, creating an environment conducive to sustainable agent development, which further enhances Real's competitive advantage in the industry.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE:OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may involve breaches of fiduciary duties impacting shareholder confidence and company reputation.
- RE/MAX Transaction Scrutiny: The sale of RE/MAX Holdings, Inc. (NYSE:RMAX) to The Real Brokerage Inc. offers either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers, prompting shareholders to consider their rights and options.
- XOMA Transaction Risks: XOMA Royalty Corporation (NASDAQ:XOMA) is involved in a sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC possibly seeking increased compensation for shareholders, affecting the future shareholder structure of the company.
- Merger Impact Analysis: The merger between The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX will result in Real shareholders owning approximately 59% of the combined entity, potentially altering the competitive landscape and necessitating a reassessment of shareholder rights and risks post-merger.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
NŌVEM Real Estate Joins Real Brokerage, Expanding NYC Presence
- Team Expansion: The 10-agent NŌVEM Real Estate team, focusing on luxury markets, joins Real Brokerage, enhancing its presence across key New York areas including Manhattan, Brooklyn, Queens, Long Island, and Westchester County.
- Agent Support Model: Founder Ethan Leifer aims to provide high-level service and support to agents, creating a highly supportive environment that allows agents to access essential resources at all career stages, thereby enhancing their personal brands.
- Industry Experience: Leifer brings over $1 billion in real estate transactions from his 13-year career, which will help Real strengthen its position in a competitive market.
- Technology and Cultural Edge: Leifer expressed admiration for Real's technology and culture, stating these elements set the company apart and effectively support agent growth and business expansion.
See More
Real Brokerage Expands into New Brunswick, Strengthening Canadian Presence
- Market Expansion: Real Brokerage Inc. expands into New Brunswick by acquiring Creativ Realty, adding 42 agents and further solidifying its market presence in Canada, marking the company's sixth province in the country.
- Sales Performance: Creativ Realty generated over $300 million in sales volume in 2025, serving all price points including the luxury market, demonstrating its strong market influence and customer base.
- Leadership Transition: Martin Gallant joins as Managing Broker for the province, bringing years of leadership experience aimed at driving Real's growth in New Brunswick and supporting future expansion opportunities across Canada.
- Cultural Alignment: Gallant noted that Real's culture aligns closely with Creativ Realty's collaborative environment, and the advantages of the technology platform and fee structure make this partnership compelling, with strong interest expected from agents looking to join.
See More
Real Brokerage Expands Kansas City Market Presence
- Agent Growth: Real Brokerage Inc. expands its agent base by 50% through the acquisition of Chartwell Realty LLC, increasing its total to over 450 agents, significantly enhancing its market share in Kansas City and solidifying its position as a leading destination for high-performing agents and teams.
- Transaction Volume: Chartwell Realty closed approximately 1,200 transactions in 2025, totaling $500 million in sales volume, ranking as the top independent full-service brokerage in Kansas City, showcasing its strong market competitiveness and operational capabilities.
- Cultural Fit and Tech Integration: The addition of Chartwell is driven by cultural alignment and the opportunity to leverage Real's technology platform for agent growth, indicating Real's ongoing momentum in attracting top-performing agents and teams, thereby enhancing its market appeal.
- Training and Support Advantage: Chartwell is renowned for its strong emphasis on training, technology, and agent support, creating an environment conducive to sustainable agent development, which further enhances Real's competitive advantage in the industry.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE:OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may involve breaches of fiduciary duties impacting shareholder confidence and company reputation.
- RE/MAX Transaction Scrutiny: The sale of RE/MAX Holdings, Inc. (NYSE:RMAX) to The Real Brokerage Inc. offers either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers, prompting shareholders to consider their rights and options.
- XOMA Transaction Risks: XOMA Royalty Corporation (NASDAQ:XOMA) is involved in a sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC possibly seeking increased compensation for shareholders, affecting the future shareholder structure of the company.
- Merger Impact Analysis: The merger between The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX will result in Real shareholders owning approximately 59% of the combined entity, potentially altering the competitive landscape and necessitating a reassessment of shareholder rights and risks post-merger.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
